VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics

Franco Lori; Davide De Forni; Elly Katabira; Denis Baev; Renato Maserati; Sandra A. Calarota; Pedro Cahn; Marco Testori; Aza Rakhmanova; Michael R. Stevens

doi:10.1371/journal.pone.0047485

Loading metrics

Open Access

Peer-reviewed

Research Article

VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics

Franco Lori ,

* E-mail: info@virostatics.it

Affiliation ViroStatics srl, Alghero, Italy
⨯
Davide De Forni,

Affiliation ViroStatics srl, Alghero, Italy
⨯
Elly Katabira,

Affiliation Makerere Medical School, Kampala, Uganda
⨯
Denis Baev,

Affiliation ViroStatics srl, Alghero, Italy
⨯
Renato Maserati,

Affiliation Infectious Diseases Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
⨯
Sandra A. Calarota,

Current address: Virology and Microbiology Department of the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Affiliation ViroStatics srl, Alghero, Italy
⨯
Pedro Cahn,

Affiliation Fundación Huesped, Buenos Aires, Argentina
⨯
Marco Testori,

Current address: Bavarian Nordic GmbH, Martinsried, BSL Bioservice Scientific Laboratories GmbH, Munich, Germany

Affiliation ViroStatics srl, Alghero, Italy
⨯
Aza Rakhmanova,

Affiliation Department of Infectious Diseases, St. Petersburg Health Department, St. Petersburg, Russia
⨯
Michael R. Stevens

Affiliation ViroStatics srl, Princeton, New Jersey, United States of America
⨯

VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics

Franco Lori,
Davide De Forni,
Elly Katabira,
Denis Baev,
Renato Maserati,
Sandra A. Calarota,
Pedro Cahn,
Marco Testori,
Aza Rakhmanova,
Michael R. Stevens

Published: October 19, 2012
https://doi.org/10.1371/journal.pone.0047485

Reader Comments

Post a new comment on this article

Media Coverage of This Article

Posted by PLOS_ONE_Group on 26 Oct 2012 at 22:45 GMT

The following article represents some of the media coverage that has occurred for this paper:

Publication: News Medical
Title: “PLoS ONE publishes review of AntiViral-HyperActivation Limiting Therapeutics clinical trial”
http://www.news-medical.n...

If you see any additional coverage of this paper in the press or blogosphere, please reply to this thread and add the link to the article.

Competing interests declared: PLOS ONE Staff

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

HIV-1
Is the Subject Area "HIV-1" applicable to this article?

Thanks for your feedback.
T cells
Is the Subject Area "T cells" applicable to this article?

Thanks for your feedback.
HIV
Is the Subject Area "HIV" applicable to this article?

Thanks for your feedback.
Immune system
Is the Subject Area "Immune system" applicable to this article?

Thanks for your feedback.
Antiretroviral therapy
Is the Subject Area "Antiretroviral therapy" applicable to this article?

Thanks for your feedback.
Antiviral therapy
Is the Subject Area "Antiviral therapy" applicable to this article?

Thanks for your feedback.
Cytotoxic T cells
Is the Subject Area "Cytotoxic T cells" applicable to this article?

Thanks for your feedback.
Immune activation
Is the Subject Area "Immune activation" applicable to this article?

Thanks for your feedback.

VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics

VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics

Reader Comments

Post Your Discussion Comment

Why should this posting be reviewed?

Thank You!

Media Coverage of This Article

Posted by PLOS_ONE_Group on 26 Oct 2012 at 22:45 GMT